Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | JAK1 | P23458 | 2/20 | 0.50 |
| ▸ | TYK2 | P29597 | 2/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12791106 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL654999 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL653531 | 0.99 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL27097154 | 0.97 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL6523477 | 0.96 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL1562901 | 0.96 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL6524693 | 0.92 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL266047 | 0.92 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL3617580 | 0.92 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL1189968 | 0.92 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119574680-A | Mass spectrum detection method for N-heterocyclic ketone and/or N-heterocyclic chiral amino compound and application thereof | 北京衍微科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-119023611-A | Real-time monitoring method for ketone-amine conversion reaction process and application thereof | 北京衍微科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-116042560-A | Mutant of recombinant aminotransferase and application thereof | 清华大学 | 2023-05-02 | — | — | CN | claimed |
| EP-4747250-A1 | KINASE INHIBITORS | The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260092073-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-04-02 | — | — | US | disclosed |
| CN-119614531-A | Application of R-aminotransferase and mutant thereof in asymmetric synthesis of chiral amine compounds | 沈阳药科大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119574680-A | Mass spectrum detection method for N-heterocyclic ketone and/or N-heterocyclic chiral amino compound and application thereof | 北京衍微科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025019585-A1 | KINASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| CN-119023611-A | Real-time monitoring method for ketone-amine conversion reaction process and application thereof | 北京衍微科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-8148387-B2 | AKT and P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-2358710-A1 | AKT AND P70 S6 KINASE INHIBITORS | Eli Lilly and Company (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011029046-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010056563-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, MTOR | SMN1; SMN2 3551/4885CYP2C19 2426/4885NPC1 847/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | SMN1; SMN2 3533/4885CYP2C19 4733/4885NPC1 2057/4885 |
| US-20260092073-A1 | NOVEL COMPOUNDS | CBR1, CBR3, ARRB1 | SMN1; SMN2 4178/4885CYP2C19 820/4885NPC1 780/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | SMN1; SMN2 3574/4885CYP2C19 262/4885NPC1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.